Angiogenesis in melanoma: an update with a focus on current targeted therapies

被引:57
|
作者
Jour, George [1 ]
Ivan, Doina [1 ]
Aung, Phyu P. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Unit 0085,1515 Holcombe Blvd, Houston, TX 77030 USA
关键词
ENDOTHELIAL GROWTH-FACTOR; PRIMARY CUTANEOUS MELANOMA; MATRIX-METALLOPROTEINASE INHIBITOR; METASTATIC MALIGNANT-MELANOMA; VON-WILLEBRAND-FACTOR; PRIMARY TUMOR-GROWTH; STAGE IV MELANOMA; PHASE-II; IN-VIVO; VASCULOGENIC MIMICRY;
D O I
10.1136/jclinpath-2015-203482
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Angiogenesis plays a crucial role in melanoma metastasis and progression. In recent years, numerous studies have investigated the prognostic and clinical significance of this phenomenon, and the development of molecular techniques has enabled us to achieve a better understanding of angiogenesis in melanoma. Herein, we review the current state of knowledge regarding angiogenesis in melanoma, including the pathophysiological, histological and immunohistochemical aspects of this phenomenon. We also review the molecular pathways involved in angiogenesis and the interplay between different components that might be manipulated in the future development of efficient targeted therapies. Recently developed targeted antiangiogenic therapies in clinical trials and included in the treatment of advanced-stage melanoma are also reviewed.
引用
收藏
页码:472 / 483
页数:12
相关论文
共 50 条
  • [21] Update on the Targeted Therapy of Melanoma
    Douglas B. Johnson
    Jeffrey A. Sosman
    Current Treatment Options in Oncology, 2013, 14 : 280 - 292
  • [22] Update on the Targeted Therapy of Melanoma
    Johnson, Douglas B.
    Sosman, Jeffrey A.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2013, 14 (02) : 280 - 292
  • [23] An update on adjuvant systemic therapies in melanoma
    Samuel, Evangeline
    Moore, Maggie
    Voskoboynik, Mark
    Shackleton, Mark
    Haydon, Andrew
    MELANOMA MANAGEMENT, 2019, 6 (03)
  • [24] Update on Gastroesophageal Adenocarcinoma Targeted Therapies
    Maron, Steven B.
    Catenacci, Daniel V. T.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2017, 31 (03) : 511 - +
  • [25] Targeted therapies and thyroid cancer: an update
    de la Fouchardiere, Christelle
    Droz, Jean-Pierre
    ANTI-CANCER DRUGS, 2011, 22 (07) : 688 - 699
  • [26] Targeted therapies in diabetic nephropathy: an update
    Gupta, Ankur
    Gupta, Preeti
    Biyani, Mohan
    JOURNAL OF NEPHROLOGY, 2011, 24 (06) : 686 - 695
  • [27] Targeted therapies in bladder cancer - an update
    Black, Peter C.
    Agarwal, Piyush K.
    Dinney, Colin P. N.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2007, 25 (05) : 433 - 438
  • [28] Novel targeted therapies in chordoma: an update
    Di Maio, Salvatore
    Yip, Stephen
    Al Zhrani, Gmaan A.
    Alotaibi, Fahad E.
    Al Turki, Abdulrahman
    Kong, Esther
    Rostomily, Robert C.
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2015, 11 : 873 - 883
  • [29] Melanoma, the hope of new targeted therapies
    Sarasin, Alain
    BIOFUTUR, 2011, (323) : 47 - 47
  • [30] Resistance to Molecularly Targeted Therapies in Melanoma
    Patel, Meet
    Eckburg, Adam
    Gantiwala, Shahina
    Hart, Zachary
    Dein, Joshua
    Lam, Katie
    Puri, Neelu
    CANCERS, 2021, 13 (05) : 1 - 26